ES2530567T3 - Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 - Google Patents

Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Download PDF

Info

Publication number
ES2530567T3
ES2530567T3 ES10186331T ES10186331T ES2530567T3 ES 2530567 T3 ES2530567 T3 ES 2530567T3 ES 10186331 T ES10186331 T ES 10186331T ES 10186331 T ES10186331 T ES 10186331T ES 2530567 T3 ES2530567 T3 ES 2530567T3
Authority
ES
Spain
Prior art keywords
level
determining
galectin
thrombospondin
identify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10186331T
Other languages
English (en)
Inventor
Yigal M Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Application granted granted Critical
Publication of ES2530567T3 publication Critical patent/ES2530567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Método para identificar un sujeto susceptible de desarrollar daño de órgano diana hipertensivo o complicaciones de insuficiencia cardíaca, que comprende: (a) determinar en una muestra biológica procedente de dicho sujeto el nivel de un marcador no miocítico seleccionado del grupo que consiste en galectina-3 y trombospondina-2; (b) comparar el nivel de dicho marcador con un nivel estándar, y (c) determinar el riesgo de desarrollar daño de órgano diana hipertensivo o complicaciones de insuficiencia cardíaca si el nivel de dicho marcador es elevado en comparación con el nivel estándar.
ES10186331T 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Expired - Lifetime ES2530567T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
ES2530567T3 true ES2530567T3 (es) 2015-03-03

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Country Status (15)

Country Link
US (5) US7888137B2 (es)
EP (4) EP1522857A1 (es)
JP (5) JP4840744B2 (es)
CN (2) CN1879022B (es)
AT (1) ATE532073T1 (es)
AU (2) AU2004284496C1 (es)
CA (2) CA2842308A1 (es)
CY (2) CY1112359T1 (es)
DK (2) DK1682907T3 (es)
ES (2) ES2377012T3 (es)
HK (2) HK1101426A1 (es)
PL (2) PL2317324T3 (es)
PT (2) PT1682907E (es)
SI (2) SI1682907T1 (es)
WO (1) WO2005040817A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
JP2010504089A (ja) 2006-09-25 2010-02-12 ユニフェルジテイト・マーストリヒト 心不全を発生させる危険がある被検者を診断および／または処置するための手段および方法
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
JP2013536408A (ja) * 2010-07-02 2013-09-19 ビージー メディシン， インコーポレイテッド ガレクチン−３測定によりモニタリングされるスタチン療法
WO2012053305A1 (ja) * 2010-10-18 2012-04-26 岐阜市 筋萎縮性側索硬化症マーカー及びその利用
EP2460890A1 (en) 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
EP2671080A1 (en) * 2011-01-31 2013-12-11 BG Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN104011544B (zh) * 2011-12-08 2018-06-05 艾莱兹疗法股份有限公司 通过血浆去除术降低半乳凝素-3的水平
WO2014052803A2 (en) * 2012-09-27 2014-04-03 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
CA2973653A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
JP6612864B2 (ja) * 2015-05-28 2019-11-27 京セラ株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
ATE476662T1 (de) * 1997-09-05 2010-08-15 Southern Medical Diagnostics P Diagnoseverfahren
ATE298423T1 (de) * 1997-10-24 2005-07-15 Shionogi & Co Verfahren zur inhibierung des abbaus von natriuretischen peptiden und verbesserte methode zum bestimmen der natriuretischen peptide
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
DK1698901T3 (da) * 1999-01-29 2008-12-08 Roche Diagnostics Gmbh Metode til at detektere N-terminalt proBNP
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
AU6794700A (en) * 1999-08-20 2001-03-19 Board Of Regents, The University Of Texas System Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1358347A2 (en) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
AU2002218026A1 (en) * 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
AU2002226079A1 (en) * 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
US7041449B2 (en) 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
CA2483105C (en) * 2002-05-13 2011-05-10 Arexis Ab Autoimmune conditions and nadph oxidase defects
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20060257946A1 (en) 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
AU2006210794A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US20070092886A1 (en) 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法

Also Published As

Publication number Publication date
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
EP2919012A1 (en) 2015-09-16
US8084276B2 (en) 2011-12-27
CA2542033C (en) 2014-04-29
ES2377012T3 (es) 2012-03-21
CN102998458B (zh) 2015-07-22
US20080193954A1 (en) 2008-08-14
PL1682907T3 (pl) 2012-03-30
AU2004284496A1 (en) 2005-05-06
JP2014115297A (ja) 2014-06-26
PL2317324T3 (pl) 2015-10-30
EP1682907B1 (en) 2011-11-02
EP2317324B1 (en) 2014-11-12
US20130189716A1 (en) 2013-07-25
ATE532073T1 (de) 2011-11-15
AU2009227844B2 (en) 2012-07-19
CY1112359T1 (el) 2015-12-09
CN1879022B (zh) 2012-10-17
AU2009227844A1 (en) 2009-11-26
EP2317324A1 (en) 2011-05-04
HK1184534A1 (zh) 2014-01-24
DK1682907T3 (da) 2012-08-13
JP2007508527A (ja) 2007-04-05
JP2011177184A (ja) 2011-09-15
JP4840744B2 (ja) 2011-12-21
US20120220532A1 (en) 2012-08-30
AU2004284496C1 (en) 2010-03-04
PT1682907E (pt) 2012-02-03
JP2010279378A (ja) 2010-12-16
SI1682907T1 (sl) 2012-03-30
EP1682907A1 (en) 2006-07-26
JP5580774B2 (ja) 2014-08-27
US20110104722A1 (en) 2011-05-05
WO2005040817A1 (en) 2005-05-06
CA2542033A1 (en) 2005-05-06
PT2317324E (pt) 2015-02-17
CY1116147T1 (el) 2017-02-08
HK1101426A1 (en) 2007-10-18
US20150037353A1 (en) 2015-02-05
JP5789009B2 (ja) 2015-10-07
US7888137B2 (en) 2011-02-15
CN1879022A (zh) 2006-12-13
SI2317324T1 (sl) 2015-11-30
CN102998458A (zh) 2013-03-27
JP2015171365A (ja) 2015-10-01
EP1522857A1 (en) 2005-04-13
DK2317324T3 (en) 2015-02-16

Similar Documents

Publication Publication Date Title
HK1184534A1 (zh) 通過測定半乳糖苷凝集素- 或者血小板反應蛋白- 的水平鑒定具有發生心力衰竭風險的受試者的方法
Monteiro et al. Quantitative histopathology of Oreochromis niloticus gills after copper exposure
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
EA200701602A1 (ru) Способ прогнозирования психических заболеваний, например аутизма и церебрального паралича
ES2113546T3 (es) Metodos y estuches de diagnostico para determinar la toxicidad de un compuesto utilizando promotores de estres bacterianos fusionados con genes reporteros.
WO2008120684A1 (ja) 急性中枢神経障害の予後判定方法
EP2293075A3 (en) Method for diagnosing neuro-degenerative disease
ATE424560T1 (de) Marker für neuromyelitis optica
NO20055025L (no) Multiplex screening for lysosomale lagringsforstyrrelser (LSD)
EA200500355A1 (ru) Способ обнаружения, характеристики и мониторинга углеводородных месторождений
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
DK1882946T3 (da) Fremgangsmåde til at bedømme rheumatold arthritis ved at måle anti-CCP og interleukin 6
DE602005007817D1 (de) Analyse-Verfahren unter Verwendung von abgeschwächter Totalreflektion
ATE374367T1 (de) Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
FR2876452B1 (fr) Procede d'optimisation de la sequence de sollicitations d'un essai accelere en contraintes echelonnees
WO2009140390A3 (en) Serum markers for type ii diabetes mellitus
BRPI0502615A (pt) método para recomendar um programa de tratamento/prevenção da acne
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
RS52875B (en) QUICK DIAGNOSTIC TEST FOR ALCHAIMER DISEASE
ATE470154T1 (de) Verfahren zur bewertung von insulinresistenz
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
DE60326269D1 (de) Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika
EA200801475A1 (ru) Полипептидные маркеры для диагностики и оценки сосудистых заболеваний